(Q37489942)

20 August 2017

1 reference

title

Advances in preclinical small molecules for the treatment of NSCLC. (English)

1 reference

20 August 2017

Qiu Zhang

1

1 reference

20 August 2017

Wei Feng

series ordinal

2

1 reference

20 August 2017

Hongyu Zhou

series ordinal

3

1 reference

20 August 2017

Bing Yan

series ordinal

4

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 June 2009

1 reference

Expert Opinion on Therapeutic Patents

20 August 2017

published in

1 reference

20 August 2017

volume

19

1 reference

20 August 2017

issue

6

1 reference

20 August 2017

page(s)

731-751

1 reference

20 August 2017

cites work

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Biomarkers in non-small cell lung cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

EGFR and cancer prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Targeted therapy in advanced non-small cell lung cancer (NSCLC): where do we stand?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

4-Anilinoquinazolines with Lavendustin A subunit as inhibitors of epidermal growth factor receptor tyrosine kinase: syntheses, chemical and pharmacological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Determination of CH330331, a novel 4-anilinoquinazoline inhibitor of epidermal growth factor receptor tyrosine kinase, in human Caco-2 monolayers by high performance liquid chromatography with ultraviolet detection: application to a trans-epithelial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

K-ras mutations in non-small-cell lung carcinoma: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Chemokines as therapeutic targets in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Overexpression of cyclooxygenase-2 in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Cyclooxygenase 2: a molecular target for cancer prevention and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Targeting blood vessels for the treatment of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Mitogen-activated protein kinase pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

The role of phosphoinositide 3-kinase pathway inhibitors in the treatment of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

The potential role of mTOR inhibitors in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax : Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

mTOR-targeted therapy of cancer with rapamycin derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Histone deacetylases and transcriptional therapy with their inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Rational development of histone deacetylase inhibitors as anticancer agents: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Increased expression of unmethylated CDKN2D by 5-aza-2'-deoxycytidine in human lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Histone deacetylase inhibitor NVP-LAQ824 sensitizes human nonsmall cell lung cancer to the cytotoxic effects of ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Preclinical antitumor activity of CI-994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Preclinical toxicity of a new oral anticancer drug, CI-994 (acetyldinaline), in rats and dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Chronic oral administration of CI-994: a phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Histone deacetylases and cancer: causes and therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

The role of DNA topoisomerases in recombination and genome stability: a double-edged sword?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Small-molecule cyclin-dependent kinase modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Cyclin-dependent kinase pathways as targets for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Progress toward the development of agents to modulate the cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Pharmacological inhibitors of cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Downregulation of XIAP and induction of apoptosis by the synthetic cyclin-dependent kinase inhibitor GW8510 in non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Heat shock protein 70 kDa: molecular biology, biochemistry, and physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Antimitotic natural products and their interactions with tubulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

DNA alkylation and interstrand cross-linking by treosulfan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

K252a inhibits the oncogenic properties of Met, the HGF receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

The insulin-like growth factor pathway in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Design, synthesis, cytoselective toxicity, structure-activity relationships, and pharmacophore of thiazolidinone derivatives targeting drug-resistant lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

P-glycoprotein-independent apoptosis induction by a novel synthetic compound, MMPT [5-[(4-methylphenyl)methylene]-2-(phenylamino)-4(5H)-thiazolone].

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Anticancer activity of 5-benzylidene-2-phenylimino-1, 3-thiazolidin-4-one (BPT) analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

JNK1-dependent antimitotic activity of thiazolidin compounds in human non-small-cell lung and colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770902967674

10.1517/13543770902967674

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference